RT Journal Article
SR Electronic
T1 Beyond Deaths per Capita: Three CoViD-19 Mortality Indicators for Temporal and International Comparisons
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.29.20085506
DO 10.1101/2020.04.29.20085506
A1 Heuveline, Patrick
A1 Tzen, Michael
YR 2020
UL http://medrxiv.org/content/early/2020/06/05/2020.04.29.20085506.abstract
AB With CoViD-19 reported in 216 countries and territories, we present 3 indicators to facilitate comparative assessments of its mortality impact: (1) CCDR, a period rate for periods of any duration that remains readily comparable to the annual Crude Death Rate (CDR); (2) CCMR, an indirectly age-and-sex standardized ratio that does not require the composition of CoViD-19 deaths; (3) expected impact on 2020 life expectancy at birth (e0(2020)).We calculate period CCDR and CCMR from estimates of CoViD-19 deaths to date for all countries/territories meeting data requirements, all provinces in China and states in the USA. Across countries, the USA ranks 14th in standardized CCMR, but values in 8 states are higher than in any country. Now declining, New York CCDR remains close to its annual CDR (5.99 v. 7.83 per thousand).We derive CCMR and CCDR values from projections for 103 countries and states, and for countries estimate the impact on e0(2020). The US reduction (.53) would bring e0(2020) to its lowest since 2008, with a single-year drop larger than for HIV in 1993 and than for opioid overdoses over 3 years. Larger reductions, between .85 and 1.19, are projected in Spain, Belgium, Chile, Brazil and Peru.These projections, (1) based on current estimates of CoViD-19 mortality that seem to underestimate the total increase in mortality to date and (2) do not factor possible new infection waves later this year, seem more likely to under-than to overestimate the eventual impact on e0(2020).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors benefited from facilities and resources provided by the California Center for Population Research at UCLA (CCPR), which receives core support (P2C-HD041022) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Publicly available data onlyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available online and can be accessed directly or through a web scraping routine that we provide at https://github.com/statsccpr/ind-cov-mort https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 https://covid19.healthdata.org/ https://www.cdc.gov/nchs/nvss/vsrr/COVID19/index.htm